1. Home
  2. VIGL vs FONR Comparison

VIGL vs FONR Comparison

Compare VIGL & FONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • FONR
  • Stock Information
  • Founded
  • VIGL 2020
  • FONR 1978
  • Country
  • VIGL United States
  • FONR United States
  • Employees
  • VIGL N/A
  • FONR N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VIGL Health Care
  • FONR Health Care
  • Exchange
  • VIGL Nasdaq
  • FONR Nasdaq
  • Market Cap
  • VIGL 89.3M
  • FONR 94.1M
  • IPO Year
  • VIGL 2022
  • FONR 1987
  • Fundamental
  • Price
  • VIGL $1.68
  • FONR $13.56
  • Analyst Decision
  • VIGL Strong Buy
  • FONR
  • Analyst Count
  • VIGL 5
  • FONR 0
  • Target Price
  • VIGL $16.33
  • FONR N/A
  • AVG Volume (30 Days)
  • VIGL 159.5K
  • FONR 8.9K
  • Earning Date
  • VIGL 03-13-2025
  • FONR 05-14-2025
  • Dividend Yield
  • VIGL N/A
  • FONR N/A
  • EPS Growth
  • VIGL N/A
  • FONR N/A
  • EPS
  • VIGL N/A
  • FONR 1.17
  • Revenue
  • VIGL N/A
  • FONR $101,570,089.00
  • Revenue This Year
  • VIGL N/A
  • FONR N/A
  • Revenue Next Year
  • VIGL N/A
  • FONR N/A
  • P/E Ratio
  • VIGL N/A
  • FONR $11.93
  • Revenue Growth
  • VIGL N/A
  • FONR N/A
  • 52 Week Low
  • VIGL $1.49
  • FONR $13.27
  • 52 Week High
  • VIGL $6.06
  • FONR $20.40
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 32.05
  • FONR 39.60
  • Support Level
  • VIGL $1.74
  • FONR $13.70
  • Resistance Level
  • VIGL $1.94
  • FONR $14.14
  • Average True Range (ATR)
  • VIGL 0.16
  • FONR 0.35
  • MACD
  • VIGL -0.02
  • FONR 0.05
  • Stochastic Oscillator
  • VIGL 4.51
  • FONR 7.50

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About FONR Fonar Corporation

Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.

Share on Social Networks: